| Budget Amount *help |
¥17,810,000 (Direct Cost: ¥13,700,000、Indirect Cost: ¥4,110,000)
Fiscal Year 2014: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2013: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2012: ¥7,150,000 (Direct Cost: ¥5,500,000、Indirect Cost: ¥1,650,000)
|
|---|
| Outline of Final Research Achievements |
We evaluated anti-proliferative potential of T cells non-virally engineered to bind to granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor (GMR.CAR T cells) against juvenile myelomonocytic leukemia (JMML) CD34+ cells. The co-culture of healthy or JMML GMR.CAR T cells with CD34+ cells of JMML patients in the presence of stem cell factor (SCF), thrombopoietin (TPO) and interleukin-3 for 2 days significantly decreased the total colony growth. Seven-day co-culture of GMR.CAR T cells with JMML CD34+ cells resulted in a marked suppression on the expansion of CD34+ cells, particularly CD34+CD38- cells, under stimulation with SCF+TPO on AGM-S3 cells. Meanwhile, GMR.CAR T cells exerted no effects on the colony growth of normal CD34+ cells. Thus, our GMR.CAR T cells may provide a novel adoptive immunotherapy for this disease.
|
